These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35217173)

  • 1. Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.
    Mazzocchi M; Goulding SR; Morales-Prieto N; Foley T; Collins LM; Sullivan AM; O'Keeffe GW
    Brain Behav Immun; 2022 May; 102():151-160. PubMed ID: 35217173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult.
    Collins LM; Adriaanse LJ; Theratile SD; Hegarty SV; Sullivan AM; O'Keeffe GW
    Mol Neurobiol; 2015; 51(3):1432-42. PubMed ID: 25065734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease.
    Mazzocchi M; Goulding SR; Wyatt SL; Collins LM; Sullivan AM; O'Keeffe GW
    Mol Cell Neurosci; 2021 Sep; 115():103642. PubMed ID: 34119632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MC1568 Inhibits Thimerosal-Induced Apoptotic Cell Death by Preventing HDAC4 Up-Regulation in Neuronal Cells and in Rat Prefrontal Cortex.
    Guida N; Laudati G; Mascolo L; Cuomo O; Anzilotti S; Sirabella R; Santopaolo M; Galgani M; Montuori P; Di Renzo G; Canzoniero LM; Formisano L
    Toxicol Sci; 2016 Dec; 154(2):227-240. PubMed ID: 27660204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
    Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
    Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
    Fletcher EJR; Moon LDF; Duty S
    BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.
    Jing X; Shi H; Zhang C; Ren M; Han M; Wei X; Zhang X; Lou H
    Neuroscience; 2015 Feb; 286():131-40. PubMed ID: 25449120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.
    Baluchnejadmojarad T; Eftekhari SM; Jamali-Raeufy N; Haghani S; Zeinali H; Roghani M
    Exp Gerontol; 2017 Dec; 100():70-76. PubMed ID: 29107062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief isoflurane anesthesia regulates striatal AKT-GSK3β signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease.
    Leikas JV; Kohtala S; Theilmann W; Jalkanen AJ; Forsberg MM; Rantamäki T
    J Neurochem; 2017 Aug; 142(3):456-463. PubMed ID: 28488766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 protects dopaminergic neurons against degeneration in animal model of Parkinson's disease.
    Smit RD; Ghosh B; Campion TJ; Stingel R; Lavell E; Hooper R; Fan X; Soboloff J; Smith GM
    Brain Res; 2024 Feb; 1824():148691. PubMed ID: 38030102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular Zn
    Tamano H; Nishio R; Morioka H; Takeda A
    Mol Neurobiol; 2019 Jan; 56(1):435-443. PubMed ID: 29705946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Sleeman IJ; Boshoff EL; Duty S
    Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.